Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Thymoma | Research

Prognostic value and immunological role of PD-L1 gene in pan-cancer

Authors: Yongfeng Wang, Hong Jiang, Liangyin Fu, Ling Guan, Jiaxin Yang, Jingyao Ren, Fangyu Liu, Xiangyang Li, Xuhui Ma, Yonghong Li, Hui Cai

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Objective

PD-L1, a target of immune checkpoint blockade, has been proven to take the role of an oncogene in most human tumors. However, the role of PD-L1 in human pan-cancers has not yet been fully investigated.

Materials and methods

Pan-cancer analysis was conducted to analyze expression, genetic alterations, prognosis analysis, and immunological characteristics of PD-L1. Estimating the correlation between PD-L1 expression and survival involved using pooled odds ratios and hazard ratios with 95% CI. The Kaplan–Meier (K-M) technique, COX analysis, and receiver operating characteristic (ROC) curves were applied to the survival analysis. Additionally, we investigated the relationships between PD-L1 and microsatellite instability (MSI), tumor mutational burden (TMB), DNA methyltransferases (DNMTs), the associated genes of mismatch repair (MMR), and immune checkpoint biomarkers using Spearman's correlation analysis. Also, immunohistochemical analysis and qRT-PCR were employed in evaluating PD-L1’s protein and mRNA expression in pan-caner.

Results

PD-L1 showed abnormal mRNA and protein expression in a variety of cancers and predicted prognosis in cancer patients. Furthermore, across a variety of cancer types, the aberrant PD-L1 expression was connected to the MSI, MMR, TMB, drug sensitivity, and tumor immune microenvironment (TIME). Moreover, PD-L1 was significantly correlated with infiltrating levels of immune cells (T cell CD8 + , neutrophil, and so on).

Conclusion

Our study provides a better theoretical basis and guidance for the clinical treatment of PD-L1.
Appendix
Available only for authorised users
Literature
1.
Wang Y, Lin K, Xu T, Wang L, Fu L, Zhang G, Ai J, Jiao Y, Zhu R, Han X, et al. Development and validation of prognostic model based on the analysis of autophagy-related genes in colon cancer. Aging (Albany NY). 2021;13(14):19028–47.PubMedCrossRef
2.
Anand P, Kunnumakkara AB, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–116.PubMedPubMedCentralCrossRef
3.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
4.
5.
6.
Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.PubMedPubMedCentralCrossRef
7.
Bishop GA, McCaughan GW. Immune activation is required for the induction of liver allograft tolerance: implications for immunosuppressive therapy. Liver Transpl. 2001;7(3):161–72.PubMedCrossRef
8.
Wang X, Li X, Wei X, Jiang H, Lan C, Yang S, Wang H, Yang Y, Tian C, Xu Z, et al. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther. 2020;5(1):38.PubMedPubMedCentralCrossRef
9.
Reck M, Remon J, Hellmann MD. First-line immunotherapy for non–small-cell lung cancer. J Clin Oncol. 2022;40(6):586–97.PubMedCrossRef
10.
Zhang C, Chong X, Jiang F, Gao J, Chen Y, Jia K, Fan M, Liu X, An J, Li J. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. J Extracell Vesicles. 2022;11(4):e12209.PubMedPubMedCentralCrossRef
11.
Karabon L, Partyka A, Ciszak L, Pawlak-Adamska E, Tomkiewicz A, Bojarska-Junak A, Roliński J, Wołowiec D, Wrobel T, Frydecka I, et al. Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients. J Immunol Res. 2020;2020:6545921.PubMedPubMedCentralCrossRef
12.
Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231–7.PubMedCrossRef
13.
Yang Y, Yu Y, Lu S. Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. Sci China Life Sci. 2020;63(10):1499–514.PubMedCrossRef
14.
Zhang Y, Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol. 2020;1248:201–26.PubMedCrossRef
15.
Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules. Curr Pharm Des. 2018;23(39):6033–41.PubMedCrossRef
16.
Nemec CM, Singh AK, Ali A, Tseng SC, Syal K, Ringelberg KJ, Ho Y-H, Hintermair C, Ahmad MF, Kar RK, et al. Noncanonical CTD kinases regulate RNA polymerase II in a gene-class-specific manner. Nat Chem Biol. 2019;15(2):123–31.PubMedCrossRef
17.
Wang H, Zhang Z, Yan Z, Ma S. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma. J Clin Lab Anal. 2021;35(1):e23565.PubMedCrossRef
18.
Chen L, Shen Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol. 2020;17(1):64–75.PubMedCrossRef
19.
Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015;5(4):1553–7.PubMedPubMedCentral
20.
Liu Q, Li C-S. Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis. Chin Med J (Engl). 2017;130(8):986–92.PubMedCrossRef
21.
22.
Kar RK, Kharerin H, Padinhateeri R, Bhat PJ. Multiple Conformations of Gal3 Protein Drive the Galactose-Induced Allosteric Activation of the GAL Genetic Switch of Saccharomyces cerevisiae. J Mol Biol. 2017;429(1):158–76.PubMedCrossRef
23.
Qi Y, Zhang W, Jiang R, Xu O, Kong X, Zhang L, Fang Y, Wang J, Wang J. Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer. Front Pharmacol. 2022;13:960323.PubMedPubMedCentralCrossRef
24.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.PubMedPubMedCentralCrossRef
25.
Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, JadidiNiaragh F, Safaei S, Asadi M, Baradaran B. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sci. 2020;259:118297.PubMedCrossRef
26.
Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of Lynch syndrome. J Pathol. 2020;250(5):518–31.PubMedCrossRef
27.
Kar RK, Hanner AS, Starost MF, Springer D, Mastracci TL, Mirmira RG, Park MH. Neuron-specific ablation of eIF5A or deoxyhypusine synthase leads to impairments in growth, viability, neurodevelopment, and cognitive functions in mice. J Biol Chem. 2021;297(5):101333.PubMedPubMedCentralCrossRef
28.
Krzyzewska IM, Maas SM, Henneman P, Lip KVD, Venema A, Baranano K, Chassevent A, Aref-Eshghi E, van Essen AJ, Fukuda T, et al. A genome-wide DNA methylation signature for SETD1B-related syndrome. Clin Epigenetics. 2019;11(1):156.PubMedPubMedCentralCrossRef
29.
Zheng M. Dose-Dependent effect of tumor mutation burden on cancer prognosis following immune checkpoint blockade: causal implications. Front Immunol. 2022;13:853300.PubMedPubMedCentralCrossRef
30.
Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, Ren J, Liu Y, You J, Wang H, et al. LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis. Front Gen. 2022;13:907774.CrossRef
31.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acid Res. 2023;51(D1):D587–92.PubMedCrossRef
32.
Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.PubMedPubMedCentralCrossRef
33.
34.
Yu L, Shen H, Ren X, Wang A, Zhu S, Zheng Y, Wang X. Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021;11(1):1–12.
35.
Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. Cancer Immunol Res. 2017;5(11):1046–55.PubMedPubMedCentralCrossRef
36.
Wang Y, Fu L, Lu T, Zhang G, Zhang J, Zhao Y, Jin H, Yang K, Cai H. Clinicopathological and prognostic significance of long non-coding RNA MIAT in human cancers: a review and meta-analysis. Front Genet. 2021;12:729768.PubMedPubMedCentralCrossRef
37.
Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X, Ren X, Ding W, Shen X, Li G. AC010973. 2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022;12(1):4272.PubMedPubMedCentralCrossRef
38.
Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Target Ther. 2016;1:16030.PubMedPubMedCentralCrossRef
39.
Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371–6.PubMedPubMedCentralCrossRef
40.
41.
Chang C-H, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJW, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229–41.PubMedPubMedCentralCrossRef
42.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87.PubMedCrossRef
43.
Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S, Qin C. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. Cancer Control. 2022;29:10732748221129452.PubMedPubMedCentralCrossRef
44.
Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016;139(5):1129–39.PubMedCrossRef
45.
Zhang Y, Yu G, Chu H, Wang X, Xiong L, Cai G, Liu R, Gao H, Tao B, Li W, et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol Cell. 2018;71(2):201–215.e7.PubMedCrossRef
46.
Bejarano L, Jordāo MJC, Joyce JA. Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021;11(4):933–59.PubMedCrossRef
47.
Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20(4):209–15.PubMedCrossRef
48.
Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–63.PubMedPubMedCentralCrossRef
49.
50.
51.
52.
53.
Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56.PubMedCrossRef
54.
55.
Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Leché A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers (Basel). 2021;13(18):4683.PubMedCrossRef
56.
Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6:5997.PubMedCrossRef
57.
58.
59.
Metadata
Title
Prognostic value and immunological role of PD-L1 gene in pan-cancer
Authors
Yongfeng Wang
Hong Jiang
Liangyin Fu
Ling Guan
Jiaxin Yang
Jingyao Ren
Fangyu Liu
Xiangyang Li
Xuhui Ma
Yonghong Li
Hui Cai
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Thymoma
Thymoma
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11267-6

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Non–small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?

Study Protocol

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

Research

Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany

Research

ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer

Research

Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC

Research

Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits